Imagyn starts sales of Site Select

Article

Imagyn Medical Technologies of Newport Beach, CA, last month concluded U.S. beta trials for its Site Select breast biopsy device. The company began the trials at 21 sites in September and, with their completion, has begun to market the device. Site

Imagyn Medical Technologies of Newport Beach, CA, last month concluded U.S. beta trials for its Site Select breast biopsy device. The company began the trials at 21 sites in September and, with their completion, has begun to market the device. Site Select allows physicians to locate and extract a biopsy specimen in one step. When the device is used with a stereotactic table, biopsies can be done with local anesthesia on an outpatient basis.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.